Literature DB >> 28337117

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease.

Jae Kwang Kim1, Sang Un Park2.   

Abstract

Entities:  

Year:  2017        PMID: 28337117      PMCID: PMC5318685          DOI: 10.17179/excli2016-820

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.

Dear Editor, Galantamine is a natural product belonging to the isoquinoline alkaloid family of compounds. It was first discovered and isolated in the 1950s from Galanthus nivalis (common snowdrop) and Galanthus woronowii (Caucasian snowdrop), members of the Amaryllidaceae family (Marco and do Carmo Carreiras, 2006[20]). Alzheimer's disease (AD) is named after Dr. Alois Alzheimer, who first identified the disease in 1906. AD slowly destroys memory and thinking skills and is the most frequently diagnosed age-related neurodegenerative disorder (Prvulovic et al., 2010[25]). Galantamine is an acetylcholinesterase (AChE) inhibitor and one of the most promising drugs available for the treatment of AD and various other memory impairments (Scott and Goa, 2000[28]; Ago et al., 2011[1]). Synthetic galantamine was first approved for the treatment of AD in Sweden in 2000 and was subsequently approved in the European Union and the United States (Heinrich and Lee Teoh, 2004[13]). In the present report, we reviewed the most recent studies on the pharmacological activity of galantamine (Table 1(Tab. 1)) (References in Table 1: Hager et al., 2016[10]; Hishikawa et al., 2016[14]; Hwang et al., 2016[15]; Wahba et al., 2016[30]; Hanafy et al., 2016[12]; Inden et al., 2016[16]; Bezerra et al., 2016[4]; Misra et al., 2016[21];Oka et al., 2016[23]; Tokuchi et al., 2016[29]; Wu et al., 2015[32]; Nakano et al., 2015[22]; Atanasova et al., 2015[3]; Fornaguera et al., 2015[8]; Woo et al., 2015[31]; Bhattacharya et al., 2015[6]; Jiang et al., 2015[17]; Prins et al., 2014[24]; Alexandrova et al., 2014[2]; Furukawa et al., 2014[9]; Caramelli et al., 2014[7]; Koola et al., 2014[19]; Kita et al., 2014[18]; Hager et al., 2014[11]; Bhattacharya et al., 2014[5]; Richarz et al., 2014[27]; Ramakrishnan et al., 2014[26]).
Table 1

Recent studies on the pharmacological activity of galantamine

Acknowledgements

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3A9A5919548).

Conflict of interest

The authors declare no conflict of interest.
  32 in total

1.  Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer's disease in ovariectomized albino-rat model.

Authors:  Sanaa M R Wahba; Atef S Darwish; Sara M Kamal
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-04-14       Impact factor: 7.328

2.  Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases.

Authors:  C Fornaguera; N Feiner-Gracia; G Calderó; M J García-Celma; C Solans
Journal:  Nanoscale       Date:  2015-06-29       Impact factor: 7.790

3.  Galantamine promotes adult hippocampal neurogenesis via M₁ muscarinic and α7 nicotinic receptors in mice.

Authors:  Yuki Kita; Yukio Ago; Kosuke Higashino; Kazuki Asada; Erika Takano; Kazuhiro Takuma; Toshio Matsuda
Journal:  Int J Neuropsychopharmacol       Date:  2014-05-12       Impact factor: 5.176

Review 4.  Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge.

Authors:  Michael Heinrich; Hooi Lee Teoh
Journal:  J Ethnopharmacol       Date:  2004-06       Impact factor: 4.360

5.  Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management.

Authors:  Amira S Hanafy; Ragwa M Farid; Maged W Helmy; Safaa S ElGamal
Journal:  Drug Deliv       Date:  2016-03-04       Impact factor: 6.419

6.  Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity.

Authors:  Mariyana Atanasova; Georgi Stavrakov; Irena Philipova; Dimitrina Zheleva; Nikola Yordanov; Irini Doytchinova
Journal:  Bioorg Med Chem       Date:  2015-07-29       Impact factor: 3.641

7.  Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.

Authors:  Ryo Tokuchi; Nozomi Hishikawa; Kosuke Matsuzono; Yoshiki Takao; Yosuke Wakutani; Kota Sato; Syoichiro Kono; Yasuyuki Ohta; Kentaro Deguchi; Toru Yamashita; Koji Abe
Journal:  Geriatr Gerontol Int       Date:  2015-05-08       Impact factor: 2.730

8.  The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.

Authors:  Niels D Prins; Wiesje A van der Flier; Dirk L Knol; Nick C Fox; H Robert Brashear; Jeffrey S Nye; Frederik Barkhof; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2014-07-21       Impact factor: 6.982

9.  Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.

Authors:  Soumee Bhattacharya; Christin Haertel; Alfred Maelicke; Dirk Montag
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

10.  Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina.

Authors:  Cristiane Bezerra da Silva; Arnildo Pott; Selene Elifio-Esposito; Luciane Dalarmi; Kátia Fialho do Nascimento; Ligia Moura Burci; Maislian de Oliveira; Josiane de Fátima Gaspari Dias; Sandra Maria Warumby Zanin; Obdulio Gomes Miguel; Marilis Dallarmi Miguel
Journal:  Molecules       Date:  2016-01-11       Impact factor: 4.411

View more
  4 in total

Review 1.  Comprehensive Review on Alzheimer's Disease: Causes and Treatment.

Authors:  Zeinab Breijyeh; Rafik Karaman
Journal:  Molecules       Date:  2020-12-08       Impact factor: 4.411

Review 2.  Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.

Authors:  Nasser A Hassan; Asma K Alshamari; Allam A Hassan; Mohamed G Elharrif; Abdullah M Alhajri; Mohammed Sattam; Reham R Khattab
Journal:  Molecules       Date:  2022-07-28       Impact factor: 4.927

Review 3.  Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders.

Authors:  Ghulam Hussain; Azhar Rasul; Haseeb Anwar; Nimra Aziz; Aroona Razzaq; Wei Wei; Muhammad Ali; Jiang Li; Xiaomeng Li
Journal:  Int J Biol Sci       Date:  2018-03-09       Impact factor: 6.580

Review 4.  Dietary Polyphenols as Therapeutic Intervention for Alzheimer's Disease: A Mechanistic Insight.

Authors:  Syed Nasir Abbas Bukhari
Journal:  Antioxidants (Basel)       Date:  2022-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.